RTP Mobile Logo

Thursday, November 8, 2018, Washington, DC, 7:00 PM – 8:30 PM

Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Application of Immune Checkpoint Inhibition in the Management of Metastatic Lung Cancer

Event Details

Location:
Marriott Marquis Washington, DC
901 Massachusetts Avenue NW
Washington, DC 20001
Hotel Phone: (202) 824-9200

Time:
6:30 PM – 7:00 PM — Registration and Dinner Buffet
7:00 PM – 8:30 PM — Educational Meeting

Meeting Room:
Liberty Ballroom (Meeting Level 4)

There is no registration fee for this event. However, preregistration is advised as seating is limited.

Faculty:
Edward B Garon, MD, MS
Associate Professor
Director, Thoracic Oncology Program
Jonsson Comprehensive Cancer Center
David Geffen School of Medicine at UCLA
Los Angeles, California

Roy S Herbst, MD, PhD
Ensign Professor of Medicine
Professor of Pharmacology
Chief of Medical Oncology
Director, Thoracic Oncology Research Program
Associate Director for Translational Research
Yale Comprehensive Cancer Center
Yale School of Medicine
New Haven, Connecticut


Vali A Papadimitrakopoulou, MD
Jay and Lori Eisenberg Distinguished Professor of Medicine
Section Chief, Thoracic Medical Oncology
Department of Thoracic/HN Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Additional faculty to be announced

Moderator:
Neil Love, MD
Research To Practice
Miami, Florida


The aforementioned “Consensus or Controversy?” symposium and the content and views expressed therein are those of Research To Practice and not of SITC.

Agenda

Event Time
6:30 PM – 7:00 PM — Registration and Dinner Buffet
7:00 PM – 8:30 PM — Educational Meeting

Overview
For this CME symposium, 4 of the world’s leading researchers with expertise in the management of lung cancer will serve as the faculty, and Research To Practice president and medical oncologist Dr Neil Love will serve as the moderator. To provide attendees access to both practical management information and perspectives on recently published and emerging data, each module will be divided into 2 distinct segments — Consensus or Controversy (CoC) discussions and Faculty Data Reviews. Each CoC segment will include presentation and informal discussion of the investigators’ responses to questions posed to them prior to the live activity. For each Faculty Data Review, the panelists will be called upon by the moderator to informally discuss available clinical trial data, ongoing research protocols and other factors that may inform current and future treatment decision-making for patients with metastatic lung cancer. Based on a preliminary evaluation of existing data sets and ongoing research efforts, it can be anticipated that the following issues will be addressed.

Topics for Discussion
  • Existing and Emerging Research Evaluating Anti-PD-1/PD-L1 Monotherapy and Combinations of Immune Checkpoint Inhibitors and Cytotoxic Therapy
  • Biologic Rationale for, Clinical Experience with and Ongoing Evaluation of Novel Combinations of Immune Checkpoint Inhibitors and Targeted Therapy or Other Immunotherapies
  • Leveraging Immune Checkpoint Inhibition for Patients with Small Cell Lung Cancer
  • Management of Toxicities Associated with Immunotherapy in NSCLC; Use of Immune Checkpoint Inhibitors in Special Patient Populations
Detailed agenda to be announced by mid-October

CE Information

Target Audience:
This activity is intended for medical oncologists, hematology-oncology fellows, surgeons and other healthcare providers involved in the treatment of lung cancer.

Learning Objectives:
At the conclusion of this activity, participants should be able to:

  • Review published research data documenting the safety and efficacy of anti-PD-1 antibodies as monotherapy or in combination with chemotherapy for newly diagnosed metastatic nonsquamous non-small cell lung cancer (NSCLC), and use this information to guide up-front decision-making for these patients.
  • Appraise recent Phase III data describing the activity and safety of combined anti-PD-L1 therapy, anti-angiogenic therapy and chemotherapy in patients with newly diagnosed metastatic nonsquamous NSCLC, and determine the potential utility of this approach in clinical practice.
  • Describe available research data documenting the efficacy and safety associated with the use of an anti-PD-1/PD-L1 antibody in combination with platinum-based chemotherapy for newly diagnosed metastatic squamous NSCLC, and evaluate the clinical and research implications of these findings.
  • Understand the biologic rationale for and published research data with the use of combinations targeting multiple immune checkpoints and, where applicable, refer patients for clinical trials or other expanded access programs.
  • Consider emerging research data and available guideline recommendations informing the use of immune checkpoint inhibitors for small cell lung cancer (SCLC).
  • Recall the design of ongoing clinical trials evaluating anti-PD-1/PD-L1 antibodies in combination with other systemic therapies for NSCLC and SCLC, and counsel appropriate patients about availability and participation.

CME Credit Form:
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement:
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

Supporters:
This activity is supported by educational grants from Genentech and Merck.

Location

Marriott Marquis Washington, DC
901 Massachusetts Avenue NW
Washington, DC 20001
Hotel Phone: (202) 824-9200

Meeting Room:
Liberty Ballroom (Meeting Level 4)

 

Registration

This activity is intended for medical oncologists, hematology-oncology fellows, surgeons and other healthcare providers involved in the treatment of lung cancer.

There is no registration fee for this event. However, preregistration is advised as seating is limited. You must be registered to attend the SITC Annual Meeting in order to attend this satellite symposium.

Registration for clinicians in practice

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

Registration for clinicians in practice »
 
Registration for other/industry professionals*

Please note, a limited number of seats are currently available for nonclinicians on a first come, first served basis.

Registration for other/industry professionals »

* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Meal service will be provided to those who attend the program, based on availability.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational programs.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.